The regulatory dust is settling — so this week, the evidence itself

One quiet study on menopausal weight loss makes our whole argument: foundation and hormones first, then the evidenced intervention — and the combination beats either alone.

What does "off-label" mean — and why does it matter for peptides?

When the FDA approves a drug, it approves it for specific uses. "Off-label" prescribing is when a licensed clinician prescribes that approved drug for a different purpose — which is legal, common, and often evidence-based.

Here's why it matters this week. Even the peptides the advisory committee reviewed were nominated for narrow uses (BPC-157 for ulcerative colitis, for instance). But if any become compoundable, clinicians could prescribe them off-label for anything. So a compound "recommended for X" can quietly become marketed for Y and Z. When you see a peptide promoted for a long list of benefits, ask which ones — if any — it was actually studied and cleared for. Usually it's a short list, or none.

The quiet period — and why it's the honest part of the story

Three weeks after the vote, the FDA has not announced whether it will accept the recommendations or open rulemaking. That silence is the news: it's the reminder that a committee vote and an actual rule are different things separated by, realistically, a year or more.

Meanwhile the status on the ground hasn't budged. BPC-157 and the rest remain in a regulatory gray zone — removed from the outright-prohibited list, but not placed on the approved-for-compounding list, and not FDA-approved. A pharmacist put the practical version plainly this month: the headlines say "FDA Approves Peptides," and that's simply wrong. Nothing legal changed at the counter. And a recent survey of direct-to-consumer clinics found many already misrepresenting the regulatory status of compounded products — some 44% of one sample referencing "FDA approval" in ways that didn't hold up. Forewarned is forearmed.

The evidence gap the regulatory noise has been hiding

This is the clearest way to understand the entire peptide landscape. On one side, you have GLP-1 medications — semaglutide, tirzepatide, and the investigational retatrutide — backed by large, published, randomized human trials: roughly 15%, 21%, and (in Phase 3) ~28% average weight loss respectively. On the other side, you have the "research peptides" that dominate the hype — BPC-157, TB-500, MOTS-c — where a 2025 systematic review of BPC-157 concluded flatly that there are no completed clinical studies describing its efficacy in humans. Extensive rodent data; a single uncontrolled 12-patient retrospective; a Phase I trial from 2015 that never published results.

The keeper concept: these two groups get lumped together under one word — "peptides" — and marketed with the same confidence. But one group has done the work and one hasn't. The GLP-1s earned their reputation in humans, at scale, in public. The hyped injectables borrowed it. When someone points to Ozempic's success to sell you BPC-157, they are transferring credibility that was never earned by the thing they're selling.

The study that quietly confirms everything this newsletter argues

A Mayo Clinic study, published in The Lancet Obstetrics, Gynaecology & Women's Health, found that postmenopausal women taking menopausal hormone therapy lost 35% more weight on tirzepatide than women on tirzepatide alone. In the numbers: about 17% total body weight loss with the combination versus 14% without, and more than double the rate of women achieving 20%+ weight loss (45% vs 18%).

Sit with why that's such a clean illustration of the Peptune thesis. The most powerful, best-evidenced tool in the metabolic toolkit — a GLP-1 — worked substantially better when the hormonal foundation was addressed first. Not instead of. Alongside, and in the right order. Hormones weren't a competitor to the medication; they were the floodlight that let the spotlight do more.

That's the whole model in one study: foundation and hormones first, then the targeted, evidenced intervention — and the combination outperforming either piece alone. It's the opposite of the gray-market pitch, which sells you the flashiest molecule in isolation and skips everything underneath.

The honest caveats, because we don't oversell even the good news: this was a retrospective study of 120 women, not a randomized trial — it shows a strong association, not proof of mechanism, and it needs prospective confirmation. And tirzepatide, like all GLP-1s, carries the muscle-and-bone-loss consideration we've covered: pair it with protein and resistance training. But the direction is striking, biologically sensible, and a real data point for a conversation with your clinician — which is exactly where a finding like this belongs.

Educational, not medical advice. Always consult a qualified clinician before starting, stopping, or changing any treatment. Regulatory details current as of writing and subject to change.

← All issues